Media Center

PRESS RELEASE 2013

MEDIA ADVISORY

ELUSYS THERAPEUTICS TO PRESENT RESULTS ON ETI-204 ANTHRAX ANTI-TOXIN

PINE BROOK, NJ – Elusys Therapeutics, Inc. (Elusys), a biopharmaceutical company developing antibody therapies to treat infectious disease, will present results of nonclinical studies evaluating the company’s anthrax anti-toxin therapy, ETI-204. ETI-204 is an investigational agent being developed for the treatment of inhalational anthrax infection.

WHAT:

Elusys researchers will make four poster presentations at the International Conference on Bacillus anthracis, Bacillus cereus, and Bacillus thuringiensis (Bacillus ACT):

  • Pharmacokinetics of ETI-204, An Anti-PA Monoclonal Antibody, In Healthy and Anthrax-Infected Rabbits and Monkeys Following IV and IM Administration
  • Development and Validation of Protective Antigen Assays From Bacillus anthracis
  • Rabbit Model of Anthrax For Exploring Complementarity of Antitoxin/Antibiotic Combination Therapy on Survival and Development of Adaptive Immunity
  • Detection of Endogenous Anti-PA Antibodies in Anthrax-Infected Rabbits After Treatment with ETI-204

WHEN:

September 1-5, 2013

WHERE:

Victoria Conference Centre, Victoria, Canada

About ETI-204

ETI-204 is a high-affinity, humanized and deimmunized monoclonal antibody that targets the protective antigen of B. anthracis and neutralizes the lethal effects of anthrax toxins by binding to Protective Antigen. It is an investigational agent being developed for treatment of inhalational anthrax. ETI-204 is formulated as a solution and is being evaluated for intravenous (IV) and/or intramuscular (IM) administration. ETI-204 efficacy and safety is being studied in animal models of inhalational anthrax and safety studies are being conducted with human volunteers. Three studies assessing pharmacokinetics and safety of intravenous (IV) administration of ETI-204 in humans have been completed. The more common adverse events related to ETI-204 administration across the three studies included upper respiratory tract infection, nausea, headache, nasal congestion and erythema. ETI-204 was granted Fast Track status and Orphan Drug Designation by the FDA.

This program is supported with federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA), the Department of Health and Human Services (HHS) under Contract Nos. HHSO100201000026C and HHS0100201100034C.

About Elusys Therapeutics, Inc.

Elusys Therapeutics, a private company based in Pine Brook, NJ, is focused on the development of antibody therapies to treat infectious disease. Elusys has been engaged in the development of ETI-204, an anthrax biowarfare countermeasures since 2000. The company has received multiple grants and contracts totaling over $200 million to support the development of ETI-204 to protect people in the event of an anthrax attack. Today, ETI-204 has advanced to the final stages of development and is on track to meet the company’s goals of receiving FDA licensure and being part of the Strategic National Stockpile. For more information, please visit www.elusys.com.

CONTACT:

Elizabeth G. Posillico, PhD
President & CEO
973-808-0222
Email: eposillico@elusys.com

SAFE HARBOR STATEMENT
This announcement includes statements that are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. This release includes forward looking statements.  Any statements, other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, and any other statements containing the words “believes”, “expects”, “anticipates”, “plans”, “estimates” and similar expressions, are forward-looking statements.  Such statements are based upon the current beliefs and expectations of management that are subject to risks, uncertainties and other important factors that could cause the company’s actual results to differ materially from those indicated by such forward-looking statements. The guidance in this presentation is only effective as of the date given and will not be updated or affirmed unless and until the Company publicly announces updated or affirmed guidance.

Media advisory-Elusys Therapeutics to present results on ETI-204 Anthrax anti-toxin

www.anthim.com

This site is intended for U.S. Healthcare Professionals. If you are a U.S. Healthcare Professional, click OK to continue